Neurent Medical has received FDA 510(k) clearance for its next-generation NEUROMARK® System, a minimally invasive device that provides ENT specialists with enhanced control, real-time feedback, and treatment confirmation for chronic rhinitis. Developed in collaboration with leading ENT experts, the updated system is now positioned for broader U.S. availability to meet growing demand.
3-month results from the CLARITY Study Show the NEUROMARK® System provides safe and effective treatment for patients with Chronic Rhinitis.
Explore 12-month safety and efficacy outcomes for treating Chronic Rhinitis with NEUROMARK®.
PARAGON 6-month Study data shows NEUROMARK® treatment benefits allergic and nonallergic rhinitis patients.
A successful round of fundraising has brought over €9 million to Neurent Medical as they develop a breakthrough therapy for Chronic Rhinitis
After closing a $25M Series B funding round, Neurent Medical prepares for commercialization of revolutionary in-office therapy.
